Tower Research Capital LLC TRC raised its position in shares of ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) by 6,543.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,696 shares of the exchange traded fund’s stock after purchasing an additional 10,535 shares during the period. Tower Research Capital LLC TRC owned approximately 0.20% of ProShares Ultra Nasdaq Biotechnology worth $612,000 at the end of the most recent reporting period.

Separately, Virtu Financial LLC raised its position in ProShares Ultra Nasdaq Biotechnology by 188.1% during the second quarter. Virtu Financial LLC now owns 20,311 shares of the exchange traded fund’s stock valued at $1,162,000 after purchasing an additional 13,262 shares in the last quarter.

NASDAQ BIB opened at $66.05 on Friday. ProShares Ultra Nasdaq Biotechnology has a twelve month low of $48.12 and a twelve month high of $70.53.

ProShares Ultra Nasdaq Biotechnology Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.

Recommended Story: What is a Stop Order?

Institutional Ownership by Quarter for ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)

Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.